Tumor resection followed by aneurysm treatmentAneurysm treatment followed by tumor resectionObservation
Tumor resection followed by aneurysm treatment: Tumor resection followed by aneurysm treatment
Aneurysm treatment followed by tumor resection: Aneurysm treatment followed by tumor resection
Observation: Tumor resection without aneurysm treatment but observation
Study summary
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm.
2. Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment.
3. Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only.
4. The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment.
5. Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial.
Exclusion Criteria:
1. Patients with recurrent sella region tumors.
2. Patients with previously treated intracranial aneurysm.
3. Pregnant or breastfeeding women.
4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.
Primary outcome measure(s)
Aneurysm progression — From enrollment to the end of treatment at 24 months The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status
Tumor related complication and progression — From enrollment to the end of treatment at 24 months The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.
Trial sites (1)
Facility
City
Region
Status
Beijing Tiantan Hospital affiliated to Capital Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.